Valneva's Trading Restriction Lifts at an Awkward Moment as Analysts Square Off Over Vaccine Prospects
Published on 07/01/2026 at 21:32 | Redaktion boerse-global.de
A 61-day block on insider share sales at Valneva expired on Tuesday, freeing executives to sell equity for the first time since the company completed an €84 million capital raise in April. The timing could hardly be worse: the stock is hovering just 5.30% above its 52-week low of €2.13, set on May 4, and has shed 41.51% of its value since the start of the year.
The lock-up was a standard condition of the April reserved offering, which saw Valneva issue roughly 16 million new shares at €2.33 apiece to bolster its vaccine pipeline and commercial operations. That injection has done little to arrest the share price slide. At €2.25, the stock now trades below the 50-day moving average of €2.40 and far beneath the 200-day line of €3.57. The relative strength index of 38.2 suggests the stock is approaching oversold territory without having reached it.
Valneva’s management has stuck to its full-year revenue forecast of €135 million to €150 million, a range that was itself cut in May after a weak start to the year. First-quarter results showed a loss per share of $0.42 on revenue of roughly $35.8 million. The 30-day annualized volatility of 38.15% underscores persistent nervousness around the name.
Should investors sell immediately? Or is it worth buying Valneva?
Analyst opinions have rarely been more polarized. Goldman Sachs downgraded Valneva from Neutral to Sell earlier this year, slashing its ADR price target from $3.25 to $2.15, citing the withdrawal of the Ixchiq vaccine and a missed primary endpoint in the Lyme disease candidate. Guggenheim, by contrast, maintains a Buy recommendation with a target of $11. Jefferies is the most bullish, reiterating a Buy and a $15 target after Phase 3 data on the Lyme vaccine.
That spread — from $2.15 to $15 — reflects deeply divergent views on Valneva’s risk-reward profile. The company’s near-term fortunes rest largely on VLA15, the Lyme vaccine candidate developed with Pfizer, which is in Phase 3 trials. Additional candidates for Shigella and Zika are also in the pipeline but remain further from market.
Should insiders choose to sell now that the restriction has lifted, the additional supply could test the support at €2.13 from May. A brief bounce at the end of June, when the stock outperformed the broader SBF-120 index by roughly three percent, failed to hold after support near €2.21 gave way. The next major catalyst — detailed Phase 3 results from the Pfizer-partnered Lyme vaccine — looms as the event most likely to break the stock out of its current malaise, for better or worse.
Ad
Valneva Stock: New Analysis - 1 July
Fresh Valneva information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
